Shared on01 Aug 25
Fair value Increased 5.14%

The consensus analyst price target for Gland Pharma has been revised downward, primarily due to a lower forecasted future P/E multiple while revenue growth expectations remain stable, resulting in a new target of ₹1662. What's in the News Brookfield Corporation and EQT AB are in advanced talks to acquire Gland Pharma from Fosun Group, with CVC Capital Partners also exploring a potential deal; the rising share price and macro/geopolitical headwinds could hinder the transaction, which could reach up to INR 257,110 million ($3 billion) if the open offer is fully subscribed.

Shared on24 Jul 25
Fair value Increased 5.72%

The upward revision in Gland Pharma’s consensus price target from ₹1678 to ₹1774 is primarily driven by a marked increase in forecast revenue growth, while profit margins remain stable. What's in the News Brookfield and EQT are in advanced talks to acquire Gland Pharma from Fosun Group, with CVC Capital and Warburg Pincus also showing interest; soaring share prices and valuation remain potential deal blockers.